Hosted by Mathys & Squire LLP
Wednesday 6 December 2023
08.30-11.30am
This invite only event is the traditional curtain raiser to the annual Genesis Conference held in the prestigious Shard in London
The seminar will bring a focussed group of expert speakers and executives together to discuss the best steps to take in terms of governance that maximise the value, security and deal conversion chances arising from leading R&D.
Translation of excellent science into better medicines and health technologies can be a complex, multi-partner journey. The passing of the baton between inventors, companies and their investors relies on robust dealmaking processes which are underpinned by each stakeholder’s due diligence. Actions such as inaccurate or incomplete data, slow responses and lack of clarity all contribute to a loss of confidence and trust from the buyer in any deal. What should researchers, tech transfer offices, start-up companies and early-stage companies be doing to ensure their data room has all the answers in due diligence?
Agenda:
08.30 Registration and coffee
09.00 Welcome – Tony Jones, CEO One Nucleus
09.10 Introduction from the Session Chair – Mo Cifci, Director in London, CFGI
09.20 IP ownership and why you must get it right – Craig Titmus, Partner, Mathys & Squire
09.40 Creating effective regulatory dossiers – Judit Molnar, VP and Head of Early Development, tranScrip
10.00 Evidencing your proposed valuation – Ralph Hughes, VP and Kyriakos Tzafestas, Director, PharmaVentures
10.20 Q&A with the speakers
10.45 Networking
11.30 Close
This event is open to attendees from the following organisation types:
- Companies undertaking R&D in the life science companies
- Investors and analysts
- Product development advisers
- Technology Transfer Offices
- Policy makers
- Translational research academics
- Media
Note: Attendance at this event is by invitation only. To request an invitation please email Tony Jones at tony@onenucleus.com
Venue and Location Information: